Doxorubicin with or without DT-7012 for advanced soft tissue sarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding a new drug called DT-7012 to standard chemotherapy (doxorubicin) works better than chemotherapy alone for two types of advanced soft tissue sarcoma. It aims to see if the combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You need a confirmed diagnosis of one of two specific sarcoma types: undifferentiated pleomorphic sarcoma (UPS) or dedifferentiated liposarcoma (DDLPS).
- Your cancer must be advanced, meaning it cannot be removed by surgery or treated with curative radiation.
- You must not have received any prior chemotherapy for advanced or metastatic disease (but prior treatment before surgery is okay if it ended more than 6 months ago).
- You need to be in good general health (able to do daily activities, with a performance status of 0 or 1) and have adequate heart, liver, and kidney function.
- You must have at least one measurable tumor that can be assessed by CT or MRI scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation therapy, a lower dose of chemotherapy, and an immunotherapy drug called toripalimab before surgery for a rare type of soft tissue sarcoma called undifferentiated pleomorphic sarcoma (UPS). The aim is to shrink the tumor and improve the chances of successful surgery.
This study tests a combination of two chemotherapy drugs—utidelone and doxorubicin—for people with advanced soft tissue sarcoma. The goal is to see if this combination can help shrink or slow the cancer.
This trial compares a combination of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) versus chemotherapy alone for people with aggressive, poorly differentiated sarcomas that have spread or cannot be removed. The goal is to see if adding immunotherapy helps shrink tumors or slow their growth better than chemotherapy alone.
This trial tests whether adding chemotherapy before surgery to a combination of immunotherapy (pembrolizumab) and radiation therapy improves outcomes for people with high-risk soft tissue sarcoma (UPS or LPS) in the arm or trunk. It aims to see if this approach can shrink tumors and reduce the chance of cancer returning.
This study tests whether adding an investigational drug called BOLD-100 to a standard chemotherapy (doxorubicin) helps people with certain types of advanced soft tissue sarcoma. It might slow tumor growth or shrink tumors.
This trial tests whether a type of chemotherapy called pegylated liposomal doxorubicin (PLD) can help keep advanced soft tissue sarcoma from growing after successful first treatment with standard anthracycline-based chemo. You may be eligible if you've completed 4-8 cycles of that initial chemo and your disease is controlled (shrank or stable).
Hear when a new Undifferentiated Pleomorphic Sarcoma (UPS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.